Atos Medical acquired by Coloplast
Context
Coloplast has reached an agreement to acquire Atos Medical from the private equity firm PAI Partners. his transaction marks a major strategic exit for PAI Partners, which acquired the company in 2016. During PAI’s five-year ownership, Atos Medical more than doubled in size, transforming from a laryngectomy specialist into a diversified ENT leader with a significant foothold in the tracheostomy market. The rationale for the acquisition is highly strategic for Coloplast, as it adds a new chronic care segment to its existing portfolio. Atos Medical’s business model is a perfect fit for Coloplast’s "Chronic Care" strategy, characterized by high-recurring revenue from medical consumables and a strong direct-to-consumer orientation. The merger allows Coloplast to leverage Atos Medical’s industry-leading margins and unique patient-reach capabilities while providing Atos with Coloplast’s massive global infrastructure to further accelerate expansion in emerging and under-penetrated markets.
In the past, Atos Medical was acquired by PAI Partners in 2016 as part of its expansion strategy.
Atos Medical, which reported an EBITDA margin of [members only] in 2021, is valued in this transaction at an EV/EBITDA multiple of [members only].
-> Deep-dive in Healthcare & Pharma market trends
Target
Founded in 1986, Atos Medical is the global market leader in laryngectomy care, specialized in supporting patients living with a neck stoma. The company’s core business model focuses on restoring speaking ability and improving pulmonary health for patients who have undergone surgical removal of the voice box or tracheostomy procedures. Its value proposition is built on a unique direct-to-consumer (DTC) model, which accounts for approximately 50% of its laryngectomy revenues, ensuring personalized care and long-term patient engagement. Atos Medical’s strategy emphasizes clinical innovation and geographical expansion, providing high-quality medical consumables such as heat and moisture exchangers (HMEs) and voice prostheses. By diversifying into the tracheostomy segment through selective acquisitions, the company has established itself as a comprehensive Ear, Nose, and Throat (ENT) specialist. With a direct presence in 30 countries and a distribution network reaching ~90 markets, Atos Medical combines technical medical expertise with a patient-centric service layer to maintain industry-leading margins and high organic growth.
Ent. Value
€1–10bn
Equity Value
[members only]
Multiples
EV / Revenue
Above 6x
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with Atos Medical
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 06/2016 | PAI PARTNERS | ATOS MEDICAL | SWEDEN | Medical Consumables |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 12/2021 | THE CARLYLE GROUP / GTCR | RESONETICS | UNITED STATES | Medical Devices |
| 12/2021 | INTEGER | OSCOR | UNITED STATES | Implants & Prosthetics |
| 11/2021 | ESSLING CAPITAL / MULTICROISSANCE / BOURRELIER GROUP | TEKNIMED | FRANCE | Implants & Prosthetics |
| 09/2021 | PERRIGO COMPANY | HRA PHARMA | FRANCE | Generics / Labs |
| 07/2021 | PARTNERS GROUP | PHARMATHEN | GREECE | CDMO |
| 07/2021 | MONTAGU PRIVATE EQUITY | INTECH MEDICAL | FRANCE | Implants & Prosthetics |
| 07/2021 | ORKLA | NUTRAQ | NORWAY | Nutrition & Dietary Supplements |
| 04/2021 | NESTLE | THE BOUNTIFUL COMPANY | UNITED STATES | Nutrition & Dietary Supplements |
| 04/2021 | DIASORIN | LUMINEX CORPORATION | UNITED STATES | Diagnostic Equipment |
| 04/2021 | NAXICAP PARTNERS | LAGARRIGUE | FRANCE | Implants & Prosthetics |
REFERENCES
Valuation range: EV €1–10bn
Revenue range: €250–500M
EV/Revenue range: Above 6x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Atos Medical by Coloplast are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: atos medical
FAQ
What transaction does this page cover?
How was the acquisition of Atos Medical by Coloplast valued, and what multiples were paid?
What was Atos Medical’s revenue at the time of the deal?
What sources support the information on this transaction?
What is mynth?